NMDA receptor channel blocker with neuroprotective activity

Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C564S355000, C564S360000, C564S367000, C564S370000, C514S653000, C514S654000, C514S655000

Reexamination Certificate

active

07022882

ABSTRACT:
Neuroprotectant agents are provided which do not contain peptides and axe protected from the degradation that limits the use of peptide-based drugs in systemic circulation. With great selectivity for NMDA receptors, the agents exert an open channel block on NMDA receptors, and protect neuronal cells containing such receptors from excitatoxic cell death.

REFERENCES:
patent: 5242947 (1993-09-01), Cherksey et al.
patent: 5432202 (1995-07-01), Cherksey et al.
patent: 5539120 (1996-07-01), Griffith et al.
patent: 5641861 (1997-06-01), Dooley et al.
patent: 5919897 (1999-07-01), Dooley et al.
patent: WO 96 40208 (1996-12-01), None
Database CAPLUS on STN, Acc. No. 1997:425990, Dooley et al., US 5,641,861 (Jun. 24, 1997) (abstract).
Database CAPLUS on STN, Acc. No. 1999:426832, Dooley et al., US, 5,919,897 (Jul. 6, 1999) (abstact).
Database CAPLUS on STN, Acc. No. 1997:140254, Dooley et al. WO 96/40208 (Dec. 19, 1996) (abstract).
Carter, Many agents that antagonize the NMDA receptor-channel complex in Vivo also cause disturbances of motor coordination. J. Pharmacol. Exp. Ther., 269:: 573-580, 1994.
Dingledine et al., “Amino acid receptors and uptake systems in the mammalian central nervous system,” Crit. Rev. Neurobiol., 4(1): 1-96, 1988.
Dorner et al., “The sysnthesis of peptidomimetic combinatorial libraries through successive amide alkylations.” Bioorg. Medicinal Chem., 4:409-715, 1996.
Ferrer-Montiel et al., “Structural determinants of the blocker binding site in glutamate and NMDA receptors channels.” Neuropharmacology, 37(2): 139-47, 1998.
Ferrer-Montiel et al., “Selected peptides targeted to the NMDA receptors channel protect neurons from excitotoxic death.” Nat. Biotechnol., 16(3): 286-91, 1998.
Houghten, R.A., “General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids.” Proc. Nat. Acad. Sci. USA, 82: 5131-5135, 1985.
Houghton et al., “Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery.” Nature, 354: 84-86, 1991.
LeBourdelles et al., “Cloning, functional coexpression, and pharmacological characterization of human cDNAs encoding NMDA receptors NR1 and NR2A subunits,” J.Neurochem., 62(6): 2091-8, 1994.
Muir and Lees, “Clinical experience with excitatory amino acid antagonist drugs.” Stroke, 26(3): 503-13, 1995.
Nefzi et al., “Parallel solid phase synthesis of tetrasubstituted diethylenetriamines via selective amide alkylation and exhaustive reduction of N-acylated dipeptides.” Tetrahedron, 55: 335-344, 1999.
Ostresh et al., “The solid phase synthesis of tri-substituted bicyclic guanidines via cyclization of reduced N-acylated dipeptides.” J.Org. Chem., 63:8622-8623, 1998.
Planells-Cases et al., “Molecular cloning, functional expression, and pharmacological characterization of an N-methyl-D-aspartate receptors subunit from human brain.” Proc. Nat. Acad. Sci. USA, 90(11): 5057-61, 1993.
Rothman and Olney, “Excitotoxicity and the NMDA receptor—still lethal after eight years.” Trends Neurosci., 18(2): 57-58, 1995.
Schinder et al., “Mitochondrial dysfunction is a primary event in glutamate neurotoxicity.” J.Neurosci., 16(19): 6125-33, 1996.
Sun et al., “Molecular cloning, chromosomal mapping and functional expression of human brain glutamate receptors.” Proc. Natl. Acad. Sci. USA, 89: 1443-1447, 1992.
Woodhull, A.M., “Ionic blockade of sodium channels in nerve.” J.Gen.Physiol., 61:687-708, 1973.
Zarei and Dani, “Ionic permeability characteristics of the N-methyl-D-aspartate receptor channel.” J.Gen.Physiol., 1103(2): 231-48, 1994.
International Search Report for International Application No. PCT/US01/42521.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

NMDA receptor channel blocker with neuroprotective activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with NMDA receptor channel blocker with neuroprotective activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NMDA receptor channel blocker with neuroprotective activity will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3595922

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.